We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+8.63%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.12B
AUM Growth
+$30M
Cap. Flow
-$55.4M
Cap. Flow %
-1.78%
Top 10 Hldgs %
52.44%
Holding
76
New
7
Increased
18
Reduced
21
Closed
10

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$114M
2
JBIO
Jade Biosciences
JBIO
+$85.4M
3
AXSM icon
Axsome Therapeutics
AXSM
+$84.9M
4
PCVX icon
Vaxcyte
PCVX
+$45.9M
5
APLS
Apellis Pharmaceuticals
APLS
+$37M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$264M
2
BBIO icon
BridgeBio Pharma
BBIO
+$69.1M
3
GH icon
Guardant Health
GH
+$53.3M
4
AMGN icon
Amgen
AMGN
+$35.2M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$30.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GH icon
1
Guardant Health
GH
$19.1B
$221M 7.09%
4,250,000
-1,193,721
-22% -$53.3M
IONS icon
2
Ionis Pharmaceuticals
IONS
$8.93B
$193M 6.2%
4,891,544
+327,337
+7% +$10.7M
PTGX icon
3
Protagonist Therapeutics
PTGX
$8.55B
$179M 5.75%
3,245,899
+245,899
+8% +$11.8M
DVAX
4
DELISTED
Dynavax Technologies
DVAX
$176M 5.66%
17,791,486
– –
INSM icon
5
Insmed
INSM
$22.4B
$176M 5.65%
1,750,000
+1,495,249
+587% +$114M
AKRO
6
DELISTED
Akero Therapeutics
AKRO
$162M 5.21%
3,042,598
-167,672
-5% -$7.62M
IMVT icon
7
Immunovant
IMVT
$7.93B
$152M 4.87%
9,500,000
– –
OCUL icon
8
Ocular Therapeutix
OCUL
$1.83B
$133M 4.25%
14,294,420
– –
APLS
9
DELISTED
Apellis Pharmaceuticals
APLS
$121M 3.89%
7,000,000
+2,000,000
+40% +$37M
CYTK icon
10
Cytokinetics
CYTK
$10.6B
$121M 3.87%
3,650,000
+576,147
+19% +$20M
GPCR icon
11
Structure Therapeutics
GPCR
$3.37B
$106M 3.41%
5,133,917
+1,033,917
+25% +$22.7M
ETNB
12
DELISTED
89bio
ETNB
$93.3M 2.99%
9,500,000
+183,667
+2% +$1.52M
AXSM icon
13
Axsome Therapeutics
AXSM
$11.7B
$83.7M 2.68%
+801,371
New +$84.9M
VRDN icon
14
Viridian Therapeutics
VRDN
$2.2B
$75.2M 2.41%
5,380,449
– –
TARS icon
15
Tarsus Pharmaceuticals
TARS
$2.55B
$70.9M 2.27%
1,750,000
+265,734
+18% +$12M
PCVX icon
16
Vaxcyte
PCVX
$7.65B
$69.9M 2.24%
2,150,000
+1,400,000
+187% +$45.9M
NRIX icon
17
Nurix Therapeutics
NRIX
$2.45B
$69.1M 2.22%
6,064,910
+564,910
+10% +$6.1M
GERN icon
18
Geron
GERN
$898M
$60.6M 1.94%
43,000,000
+4,823,749
+13% +$6.84M
IMCR icon
19
Immunocore
IMCR
$1.7B
$56.5M 1.81%
1,800,000
+388,598
+28% +$12.1M
RARE icon
20
Ultragenyx Pharmaceutical
RARE
$2.46B
$49.1M 1.57%
1,350,000
– –
MAZE
21
Maze Therapeutics
MAZE
$1.51B
$48.5M 1.55%
3,948,910
+679,784
+21% +$7.07M
ANIP icon
22
ANI Pharmaceuticals
ANIP
$1.86B
$45.7M 1.46%
700,000
– –
XENE icon
23
Xenon Pharmaceuticals
XENE
$6.1B
$42.3M 1.36%
1,350,000
+350,000
+35% +$11.4M
DNTH icon
24
Dianthus Therapeutics
DNTH
$5.69B
$41.6M 1.33%
2,233,148
-124,554
-5% -$2.34M
CLDX icon
25
Celldex Therapeutics
CLDX
$2.94B
$40.7M 1.31%
2,000,000
– –
1
2 3 4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Deep Track Capital held 76 positions worth $3.12B, up 0.97% from $3.09B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deep Track Capital's Q2 2025 filing shows 7 new, 18 increased, 21 reduced and 10 closed positions. Its largest new stake was Jade Biosciences: 2,509,301 shares worth $25.1M. The largest sale was Intra-Cellular Therapies Inc., an estimated $264M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

  • Deep Track Capital's largest Q2 2025 buy was Jade Biosciences: 2,509,301 shares worth $25.1M.
  • Deep Track Capital added most to Insmed in Q2 2025, an estimated $114M increase.
  • Deep Track Capital's biggest Q2 2025 reduction was BridgeBio Pharma, cutting an estimated $69.1M.
  • Deep Track Capital fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $264M.
  • Deep Track Capital's ten largest holdings make up 52% of its $3.12B portfolio in Q2 2025.
  • Deep Track Capital opened 7 new positions and closed 10 in Q2 2025.
  • Deep Track Capital's portfolio value rose 0.97% quarter-over-quarter to $3.12B.

Based on Deep Track Capital's 13F filing for Q2 2025, filed 14 Aug 2025.